Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.46 |
| ▸ | F3 | P13726 | 2/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28307709 | 0.83 | L3MBTL1 (0.55) | LMNAGSK3BTAS1R3TAS1R1F3 | |
| Amiloxate SCHEMBL8095776 | 0.81 | LMNA (1.00) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| Amiloxate SCHEMBL15764 | 0.81 | LMNA (1.00) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| Amiloxate SCHEMBL15765 | 0.81 | LMNA (1.00) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| Amiloxate SCHEMBL2228053 | 0.81 | LMNA (1.00) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| Amiloxate SCHEMBL2228049 | 0.81 | LMNA (1.00) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| Amiloxate SCHEMBL31304727 | 0.80 | LMNA (0.97) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| Amiloxate SCHEMBL1768923 | 0.76 | LMNA (0.90) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| 4-Methoxycinnamic Acid SCHEMBL27842260 | 0.76 | TDP1 (0.63) | LMNATDP1GSK3BTAS1R3TAS1R1 | |
| SCHEMBL8648429 | 0.76 | GSK3B (0.61) | LMNAGSK3BF3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2425810-B1 | Sunscreen compositions | NEUTROGENA CORP (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2275177-B1 | Topical composition fluorescence detection | JOHNSON & JOHNSON CONSUMER (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8236287-B2 | Sunscreen compositions | NEUTROGENA CORPORATION (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120058192-A1 | SUNSCREEN COMPOSITIONS | KENVUE BRANDS LLC | 2012-03-08 | — | — | US | disclosed |
| EP-2425810-A2 | Sunscreen compositions | NEUTROGENA CORPORATION (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2275177-A1 | Topical composition fluorescence detection | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2275176-A1 | Topical sunscreen composition fluorescence detection | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010138710-A2 | TOPICAL SKIN CARE COMPOSITIONS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305064-A1 | TOPICAL SKIN CARE COMPOSITIONS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100303910-A1 | TOPICAL SKIN CARE COMPOSITIONS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20050196347-A1 | High lipid content sprayable emulsions | BERILLOUET ANNE-SOPHIE (FR) | 2005-09-08 | — | — | US | disclosed |
| EP-1537854-A1 | High lipid content sprayable emulsions | Johnson & Johnson Consumer France SAS (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050048856-A1 | A dried porous or absorbent sheet of a nonwoven material where an aqueous and a lipid phase lipid phase of an oily nature have been applied; cleansing wipes for babies with improved skincare benefits in one single lotion; delivery of active ingredient; antisoilants for oil- and water-compatible soils | JOHNSON & JOHNSON GMBH (DE) | 2005-03-03 | — | — | US | disclosed |
| US-20050031847-A1 | Products comprising a sheet and a lipid and aqueous phase | MARTENS NICHOLAS (DE) | 2005-02-10 | — | — | US | disclosed |
| EP-1408926-A1 | DRY PRODUCTS COMPRISING A SHEET AND TWO PHASES | JOHNSON & JOHNSON GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| EP-1408927-A1 | PRODUCTS COMPRISING A SHEET AND A LIPID AND AQUEOUS PHASE | Johnson and Johnson GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003005982-A1 | PRODUCTS COMPRISING A SHEET AND A LIPID AND AQUEOUS PHASE | JOHNSON & JOHNSON GMBH (DE) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003005983-A1 | DRY PRODUCTS COMPRISING A SHEET AND TWO PHASES | JOHNSON & JOHNSON GMBH (DE) | 2003-01-23 | — | — | WO | disclosed |
| EP-1275370-A1 | Products comprising a sheet and a lipid and aqueous phase | Johnson and Johnson GmbH (DE) | 2003-01-15 | — | — | EP | disclosed |
| EP-1275371-A1 | Dry products comprising a sheet and two phases | Johnson and Johnson GmbH (DE) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305064-A1 | TOPICAL SKIN CARE COMPOSITIONS | CUTA, POLR1C, IL33 | LMNA 1095/4885TDP1 1429/4885GSK3B 807/4885 |
| US-20100303910-A1 | TOPICAL SKIN CARE COMPOSITIONS | CUTA, DSG1, POLR1C | LMNA 896/4885TDP1 1094/4885GSK3B 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.